Jade Biosciences, Inc. JBIO · Stock Open Jade Biosciences, Inc. in new tab
Analyst price targets
Recent rating changes, newest first
Jade Biosciences, Inc. Analysis (JBIO)
Is Jade Biosciences, Inc. a good investment? Jade Biosciences, Inc. (JBIO) is currently trading at 14.59 USD. Market analysts have a consensus price target of 50.13 USD. This suggests a potential upside from current levels.
Earnings Schedule: Jade Biosciences, Inc. is expected to release its next earnings report on Nov. 12, 2026. The market consensus estimate for Forward EPS is -2.66.
Investor FAQ
Does Jade Biosciences, Inc. pay a dividend?
No, it does not currently pay a dividend.
What asset class is Jade Biosciences, Inc.?
Jade Biosciences, Inc. is classified as a Stock. You can compare it against its peer in the "Related Symbols" list.
When is the next earnings date?
The next earnings date is projected to be Nov. 12, 2026. The company currently has a trailing EPS of -1.92.
Company Profile
Jade Biosciences, Inc. operates as a biotechnology company that develops therapies for inflammation and immunology indications in patients living with autoimmune diseases. It develops JADE101, a monoclonal antibody to block the A PRoliferation Inducing Ligand protein, which is in phase 1 clinical trial. The company also develops JADE201 and JADE-003, which are in preclinical development stage. Jade Biosciences, Inc. has a collaboration agreement with Paragon Therapeutics, Inc. Jade Biosciences, Inc. is based in Waltham, Massachusetts.
| Year | Total Dividends |
|---|---|
| ▸2025 |
2.40 USD
|
| April 29, 2025 | 2.4000 |
| Split Date | Split Ratio to 1 |
|---|---|
| April 29, 2025 | 0.03 |
Community Discussion